Sermorelin — the entry GHRH peptide.

Sermorelin is a synthetic 29-amino-acid fragment of growth- hormone-releasing hormone (GHRH). It binds the GHRH receptor on the pituitary and prompts the pituitary to release the body's own growth hormone in the natural pulsatile pattern GH is supposed to be released in.

This is the key clinical advantage of GHRH peptides versus direct exogenous HGH: Sermorelin extends what the body is already doing. Exogenous HGH replaces that signal and suppresses endogenous production. Sermorelin doesn't.

Sermorelin's half-life is short (10–15 minutes). It binds the receptor, triggers a GH pulse, and clears. That short half-life is why most clinical protocols dose at night — aligning the supplemental pulse with the natural overnight GH surge.

Unlike the older CJC-1295 + Ipamorelin combo (which hits both the GHRH receptor AND the ghrelin secretagogue pathway), Sermorelin is GHRH-only. Single mechanism, milder response, fewer drug interactions to manage.

Sermorelin tends to be the right peptide for:

• Patients new to peptide therapy who want the gentlest entry
• Patients prioritizing sleep depth and recovery over body composition
• Patients sensitive to the stronger response of CJC/Ipa
• Patients on a tighter budget — Sermorelin is the lowest-cost GH-supporting protocol we offer

For patients prioritizing visible body-composition change or who want full dual-pathway GH support, the CJC-1295 / Ipamorelin combo is usually a better fit.

Typical clinical protocols dose Sermorelin at 200–500mcg by subcutaneous injection, 5 nights per week (Monday-Friday, with weekends off so the receptor doesn't desensitize). Dosing is at bedtime on an empty stomach — eating dampens the GH response.

Exact dose and frequency come from your consultation. Higher starting doses for active training-block use; lower for recovery-only or sleep-only goals.

Most patients notice deeper, more restful sleep in the first 1–2 weeks. Energy and recovery improvements typically follow at 4–6 weeks. Visible body-composition changes (lean mass, reduced visceral fat) take 8–12 weeks of consistent dosing.

We re-test IGF-1 at week 6–8 to confirm the physiologic response and adjust if needed. Annual full panel after that.

Vektor prescribes Sermorelin through our U.S. 503A pharmacy partner with deep peptide compounding capability. Standard formats include 9mg / 15mg vials at 2.5mg/mL. Shipping is cold-chain when required.

Sermorelin is the most common first-peptide we prescribe. New patients usually start here, and often graduate to CJC/Ipa or add Tesamorelin once they've seen how their body responds.